Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties

Journal of Pharmaceutical Sciences

Volumn 99, Issue 6, 2010, Pages 2839-2853

  Ho, Emmanuel A ^a   Ramsay, Euan ^b   Ginj, Mihaela ^a   Anantha, Malathi ^a   Bregman, Isaiah ^a   Sy, Jonathan ^a,c   Woo, Janet ^a,c   Osooly Talesh, Maryam ^a   Yapp, Donald T ^a,c   Bally, Marcel B ^a,b,c  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b Center for Drug Research and Development   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cancer; Cationic liposome; Drug delivery; Endothelial cell; Nanotechnology; Pegylation; Tumor vasculature; Zeta potential

Indexed keywords

CATIONIC LIPOSOME; LIPOSOME; MACROGOL 20000; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; MOUSE; NONHUMAN; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 77951523558     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22043     Document Type: Article

References (60)

1. Folkman J. 1992. The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65-71.
2. Folkman J. 2003. Fundamental concepts of the angiogenic process. Curr Mol Med 3:643-651.
3. Shimizu K, Oku N. 2004. Cancer anti-angiogenic therapy. Biol Pharm Bull 27:599-605.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
5. Gately S, Kerbel R. 2001. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7:427-436. (Pubitemid 33759008)
6. Shimizu K, Asai T, Fuse C, Sadzuka Y, Sonobe T, Ogino K, Taki T, Tanaka T, Oku N. 2005. Applicability of anti-neovascular therapy to drug-resistant tumor: Suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. Int J Pharm 296:133-141. (Pubitemid 40693382)
7. Hudis CA. 2005. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 19:26-31.
8. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. 2003. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346. (Pubitemid 36951001)
9. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. 2006. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 12:5190-5198.
10. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, Sudhakar A, Kalluri R. 2004. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64:1570-1574. (Pubitemid 38428672)
11. Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, Dragowska WH, Ramsay E, Anantha M, Ruth TJ, Adam MJ, Yung A, Kozlowski P, Minchinton AI, Ng SS, Bally MB, Yapp DT. 2008. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res 14:7260-7271.
12. Sharma US, Sharma A, Chau RI, Straubinger RM. 1997. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 14:992-998. (Pubitemid 27371396)
13. Zhou R, Mazurchuk R, Straubinger RM. 2002. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62:2561-2566. (Pubitemid 34462735)
14. Teifel M, Heine LT, Milbredt S, Friedl P. 1997. Optimization of transfection of human endothelial cells. Endothelium 5:21-35. (Pubitemid 27165887)
15. Dabbas S, Kaushik RR, Dandamudi S, Kuesters GM, Campbell RB. 2008. Importance of the liposomal cationic lipid content and type in tumor vascular targeting: Physicochemical characterization and in vitro studies using human primary and transformed endothelial cells. Endothelium 15:189-201.
16. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM. 1998. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 101:1401-1413. (Pubitemid 28166838)
17. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. 2003. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 105: 561-567. (Pubitemid 36578564)
18. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, Wolff K, Petzelbauer P. 2003. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 120:476-482.
19. Sengupta S, Tyagi P, Velpandian T, Gupta YK, Gupta SK. 2000. Etoposide encapsulated in positively charged liposomes: Pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 42:459-464.
20. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M. 2002. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 62:4282-4288. (Pubitemid 34827283)
21. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. 1995. Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 92:9742-9746.
22. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. 1997. Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 15:647-652.
23. Hofland HE, Nagy D, Liu JJ, Spratt K, Lee YL, Danos O, Sullivan SM. 1997. In vivo gene transfer by intravenous administration of stable cationic lipid/DNA complex. Pharm Res 14: 742-749.
24. Ishiwata H, Suzuki N, Ando S, Kikuchi H, Kitagawa T. 2000. Characteristics and biodistribution of cationic liposomes and their DNA complexes. J Control Release 69:139-148.
25. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. 2002. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 22:225-250. (Pubitemid 35222733)
26. Chiu GN, Bally MB, Mayer LD. 2002. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560:37-50.
27. Campbell RB, Ying B, Kuesters GM, Hemphill R. 2009. Fighting cancer: From the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 98:411-429.
28. Hope M, Bally M, Webb G, Cullis P. 1985. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812:55-65.
29. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. 2007. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: Relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta 1768:1367-1377. (Pubitemid 46782695)
30. Claassen E. 1992. Post-formation fluorescent labelling of liposomal membranes. In vivo detection, localisation and kinetics. J Immunol Methods 147:231-240.
31. Bally MB, Mayer LD, Hope MJ, Nayar R. 1993. Pharmacodynamics of liposomal drug carriers: Methodological considerations. In: Gregoriadis G, editor. Liposome technology. 2nd edition. London, United Kingdom: CRC Press, Inc. pp 27-42.
32. Chonn A, Semple SC, Cullis PR. 1992. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem 267:18759-18765.
33. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. 1998. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307-314. (Pubitemid 28197296)
34. Litzinger DC, Brown JM, Wala I, Kaufman SA, Van GY, Farrell CL, Collins D. 1996. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta 1281: 139-149. (Pubitemid 26194106)
35. Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP, Munn LL. 2002. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 62:6831-6836. (Pubitemid 35424069)
36. Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB. 2008. Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK). Mol Cancer Ther 7:59-70.
37. Dandamudi S, Campbell RB. 2007. The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 28:4673-4683. (Pubitemid 47260702)
38. Noone PG, Hohneker KW, Zhou Z, Johnson LG, Foy C, Gipson C, Jones K, Noah TL, Leigh MW, Schwartzbach C, Efthimiou J, Pearlman R, Boucher RC, Knowles MR. 2000. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 1:105-114.
39. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans MJ, Colledge WH, Higgins CF, Webb AK, Gill DR. 2000. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7:1156-1165.
40. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. 2001. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial. J Clin Oncol 19:3422-3433.
41. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, Dellian M. 2004. Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 110:117-124.
42. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K, Dellian M. 2003. Neovascular targeting therapy: Paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9:2335-2341.
43. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. 1991. Liposomes containing synthetic lipid derivatives of poly(-ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
44. Allen TM, Hansen C, Rutledge J. 1989. Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 981:27-35.
45. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. 1991. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464.
46. Koyama Y. 2006. Non-viral gene therapy gene design and delivery. 1st edition. Tokyo: Springer. p 15.
47. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. 1998. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372:272-282.
48. Dandamudi S, Campbell RB. 2007. Development and characterization of magnetic cationic liposomes for targeting tumor microvasculature. Biochim Biophys Acta 1768:427-438.
49. Matsumura H, Furusawa K. 1989. Electrical phenomena at the surface of phospholipid membranes relevant to the sorption of ionic compounds. Adv Colloid Interface Sci 30:71-109.
50. Makino K, Yamada T, Kimura M, Oka T, Ohshima H, Kondo T. 1991. Temperature- and ionic strength-induced conformational changes in the lipid head group region of liposomes as suggested by zeta potential data. Biophys Chem 41:175-183.
51. Hattori Y, Hashida M. 2006. Evaluation of size and zeta potential of DNA/carrier complexes. Tokyo: Springer.
52. Awasthi VD, Garcia D, Goins BA, Phillips WT. 2003. Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits. Int J Pharm 253:121-132.
53. Bennett C, Zuckerman JE, Kornbrust D, Sasmor HM, Leeds J, Crooke ST. 1996. Pharmacokinetics in mice of a [3H]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J Control Release 41:121-130.
54. Jurima-Romet M, Shek PN. 1991. Lung uptake of liposome-entrapped glutathione after intratracheal administration. J Pharm Pharmacol 43:6-10.
55. Shek PN, Suntres ZE, Brooks JI. 1994. Liposomes in pulmonary applications: Physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 2:431-442.
56. Harvie P, Wong FM, Bally MB. 2000. Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles. J Pharm Sci 89:652-663.
57. Shi F, Wasungu L, Nomden A, Stuart MC, Polushkin E, Engberts JB, Hoekstra D. 2002. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions. Biochem J 366:333-341.
58. Johnstone SA, Masin D, Mayer L, Bally MB. 2001. Surface-associated serum proteins inhibit the uptake of phosphatidyl-serine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513:25-37.
59. Halter M, Antia M, Vogel V. 2005. Fibronectin conformational changes induced by adsorption to liposomes. J Control Release 101:209-222.
60. Kim S, Bell K, Mousa SA, Varner JA. 2000. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 156:1345-1362.